#United States #Webinar #Princeton #sepsis #CytoSorbents

CytoSorbents to Host Global Webinar Addressing Sepsis

In recognition of World Sepsis Day, CytoSorbents Corporation, a notable player in the field of life-threatening conditions management, is set to conduct a global webinar titled, "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb." This event will take place on September 10, 2025, and aims to discuss innovative treatment approaches for sepsis, a critical health challenge affecting millions worldwide.

Event Details

The webinar will be led by Dr. Phillip Chan, CEO of CytoSorbents, who will be joined by prominent experts and clinicians from around the globe. These panelists will share their insights and best practices in utilizing CytoSorb® therapy, which has shown promise in managing severely ill patients suffering from sepsis.

Scheduled time is 11 AM EDT, with interested participants required to register prior to the event. More information regarding registration can be found at CytoSorb Webinar.

Expert Insights

Highlighted speakers include:

• - Dr. Tobias Hübner, Chief Physician at the Intensive Care Unit, Hospital of Münsterlingen, Switzerland.
• - Prof. Zsolt Molnár, Head of the Department of Anesthesiology, Semmelweis University, Hungary.
• - Dr. Kevin Pilarczyk, Chief Physician of Intensive Care and Emergency Medicine, Hochsauerland Hospital, Germany.

The shared content will include comprehensive reviews of:
1. The integration of CytoSorb with antibiotics to constructively address sepsis pathology.
2. Best practices for early and sustained application of CytoSorb based on empirical evidence.
3. The role of CytoSorb in preventing organ failures, which is crucial to the treatment process.

Sepsis and Septic Shock Overview

Sepsis, arising from an uncontrolled immune response to infections, affects an alarming 49 million individuals each year and tragically claims 11 million lives globally. Septic shock, a severe manifestation of this condition, leads to dire outcomes, including organ failure and a mortality rate of up to 50%. In spite of numerous research efforts, effective therapeutic options remain limited.

CytoSorbents Corporation has devoted over a decade collaborating with healthcare professionals and researchers to refine their CytoSorb technology, which involves specialized blood purification techniques to eliminate harmful toxins from the bloodstream. Evidence gathered from clinical practice has demonstrated that CytoSorb, when applied appropriately, significantly improves patient survival rates and recovery outcomes.

Dr. Chan emphasized, "The ongoing battle against sepsis represents a formidable challenge in critical care, despite advancements in antibiotic and support treatments. Our commitment lies in continuing to innovate and provide effective solutions through CytoSorb technology."

For additional information and insights, follow CytoSorbents’ septic shock blog series and access testimonials from healthcare providers globally about their experiences with CytoSorb in managing critical health situations.

In conclusion, CytoSorbents invites all interested parties to participate in the upcoming webinar aimed at deepening the understanding of sepsis management and enhancing patient lives on World Sepsis Day.

For more information about CytoSorbents and its innovative treatment technologies, please visit CytoSorbents Corporation.

About CytoSorbents Corporation

CytoSorbents is at the forefront of medical innovations in the treatment of critical illnesses through blood purification technologies. Their products, including CytoSorb, are currently approved in Europe and utilized in various clinical settings worldwide. The company remains dedicated to advancing therapies that can ultimately enhance care in the intensive care and cardiac surgery environments.